Human Papillomavirus Vaccination for Men

Advancing Policy and Practice

Peter A Newman; Ashley Lacombe-Duncan


Future Virology. 2014;9(12):1033-1047. 

In This Article

HPV Vaccination for Men

The quadrivalent HPV vaccine (HPV4; Gardasil) is 90% effective in preventing a variety of types of HPV infection and genital warts in young men,[2] and anal epithelial neoplasias that are precursors to anal cancer.[28] The vaccine protects against low-risk types HPV-6 and HPV-11, which are associated with genital warts, and high-risk types HPV-16 and HPV-18, which are associated with various cancers.[3]

The US Advisory Committee on Immunization Practices (ACIP) licensed HPV4 for boys and young men in 2009, 3 years after licensing HPV4 for girls.[1] HPV4 is recommended for boys aged 11–21 years, with approval for administration up to age 26, in order to prevent genital warts and anal cancer.[29] HPV4 is also recommended for MSM through the age of 26.[29] The high effectiveness of the HPV4 vaccine, along with increasing evidence of causal links between HPV-16 and anal, penile and oral cancers,[15,16,30,31] indicate that HPV4 vaccination programs can significantly reduce the burden of HPV-related diseases and cancers among men.

Nevertheless, in 2013 the proportion of boys in the USA aged 13–17 years who had received at least one dose of HPV4 vaccine was estimated at 34.6%.[32] This represents a significant increase from the 8.3% coverage in 2011; however, only 13.9% of boys aged 13–17 years completed the recommended three-dose HPV4 vaccine series.[32]